Genomically informed active surveillance in intermediate risk prostate cancer.
To investigate if genomic-based risk stratification at the time of diagnosis with favourable intermediate risk prostate cancer will reduce the number of people receiving radical treatment without compromising long term oncological outcomes. Genomic tests used in risk stratification are germline, somatic, and Decipher.
APC is a study site for this ANZUP trial with Prof Niall Corcoran as principal investigator (PI).
Click here for more information on the GenI-AIRSPACE trial.
